# A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans

Study · id `cardio:ct-nct02877173` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02877173](<https://clinicaltrials.gov/study/NCT02877173>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02877173

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.

## Technical summary

Registry record NCT02877173. Randomized; double masking; primary purpose treatment. Start 2016-08 (registry gives no type); primary completion 2017-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT02877173, source copy `cardio:ctgov-nct02877173-2017-03-10`, retrieved 2026-10-31)
- Start date: 2016-08 (registry gives no type) (ClinicalTrials.gov record NCT02877173, source copy `cardio:ctgov-nct02877173-2017-03-10`, retrieved 2026-10-31)
- Primary completion: 2017-07 (anticipated) (ClinicalTrials.gov record NCT02877173, source copy `cardio:ctgov-nct02877173-2017-03-10`, retrieved 2026-10-31)
- Completion: 2017-12 (anticipated) (ClinicalTrials.gov record NCT02877173, source copy `cardio:ctgov-nct02877173-2017-03-10`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT02877173, source copy `cardio:ctgov-nct02877173-2017-03-10`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02877173-2017-03-10`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans
- Condition: Arteriosclerosis Obliterans
- Intervention (Drug): Alprostadil Liposomes for Injection
- Intervention (Drug): Alprostadil Injection
- Lead sponsor: Guangzhou Yipinhong Pharmaceutical CO.,LTD
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)

## Provenance

Content hash: b15bb906a79f8e41d9ac953dcb31d25c96cd9a2d1bca5079af52e617a7fb8490
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
